Perspective Therapeutics (CATX) Interest Coverage Ratio (2010 - 2026)
Perspective Therapeutics (CATX) reported Interest Coverage Ratio of 9.95 for Q1 2026, up 79.8% on a YoY basis from 5.54 in Q1 2025, and up 99.97% sequentially from 38282.0 in Q4 2025.
Perspective Therapeutics (CATX) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 17 years of Interest Coverage Ratio data on file, last reported at 9.95 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 79.8% year-over-year to 9.95; the trailing twelve-month figure through Mar 2026 stood at 38.9 (up 82.72% YoY), and the FY2025 full-year result was 0.03, down 46.14% from the prior year.
- Interest Coverage Ratio grew to 9.95 in Q1 2026, from 38282.0 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.71 in Q2 2023 to a low of 38282.0 in Q4 2025.
- A 5-year average of 2789.13 and a median of 11.45 in 2025 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio surged 99.8% in 2024 and slumped 3559690.28% in 2025, its largest moves.
- Tracing CATX's Interest Coverage Ratio over 5 years: stood at 33.56 in 2022, then sank by 1481.38% to 530.73 in 2023, then surged by 99.8% to 1.08 in 2024, then slumped by 3559690.28% to 38282.0 in 2025, then jumped by 99.97% to 9.95 in 2026.
- Business Quant data shows CATX's Interest Coverage Ratio at 9.95 in Q1 2026, 38282.0 in Q4 2025, and 12.94 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 0.90 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.32 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 13.19 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 2.15 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 1.19 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 82.35 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -2.90 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 5.36 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | -9.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.95 |
| Dec 31, 2025 | -38,282.00 |
| Sep 30, 2025 | -12.94 |
| Jun 30, 2025 | -9.27 |
| Mar 31, 2025 | -49.28 |
| Dec 31, 2024 | -1.08 |
| Sep 30, 2024 | -51.62 |
| Jun 30, 2024 | -52.44 |
| Mar 31, 2024 | -9.27 |
| Dec 31, 2023 | -530.73 |
| Sep 30, 2023 | -4.29 |
| Jun 30, 2023 | -0.71 |
| Mar 31, 2023 | -0.75 |
| Mar 31, 2022 | -33.56 |
| Sep 30, 2021 | -6.63 |
| Jun 30, 2021 | 1.37 |
| Mar 31, 2021 | -0.32 |
| Dec 31, 2020 | -3.31 |
| Sep 30, 2020 | -2.61 |
| Jun 30, 2020 | -5.10 |